The effects of 4'-esterified resveratrol derivatives on calcium dynamics in breast cancer cells

Molecules

Volumn 22, Issue 11, 2017, Pages

  Peterson, Joshua A ^a   Doughty, Hayden P ^a   Eells, Austin J ^a   Johnson, Trent A ^a   Hastings, Jordan P ^a   Crowther, Colton M ^b   Andrus, Merritt B ^b   Kenealey, Jason D ^a  

^a BRIGHAM YOUNG UNIVERSITY   (United States)

^b Brigham Young University   (United States)

Author keywords

Calcium signaling; Cell viability; MDA MB 231; P53; Resveratrol derivatives

Indexed keywords

ANTINEOPLASTIC AGENT; CALCIUM; ESTER; ESTROGEN RECEPTOR; RESVERATROL; STILBENE DERIVATIVE;

CALCIUM SIGNALING; CELL PROLIFERATION; CELL SURVIVAL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECT; FEMALE; HUMAN; METABOLISM; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CALCIUM; CALCIUM SIGNALING; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; ESTERS; FEMALE; HUMANS; MOLECULAR STRUCTURE; RECEPTORS, ESTROGEN; STILBENES;

EID: 85035211767     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules22111968     Document Type: Article

References (31)

1. Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2016. CA Cancer J. Clin. 2016, 66, 7–30. [CrossRef] [PubMed]
2. Chavez, K.J.; Garimella, S.V.; Lipkowitz, S. Triple negative breast cancer cell lines: One tool in the search for better treatment of triple negative breast cancer. Breast Dis. 2010, 32, 35–48. [CrossRef] [PubMed]
3. Foulkes, W.D.; Smith, I.E.; Reis-Filho, J.S. Triple-Negative Breast Cancer. N. Engl. J. Med. 2010, 363, 1938–1948. [CrossRef] [PubMed]
4. Azimi, I.; Roberts-Thomson, S.J.; Monteith, G.R. Calcium influx pathways in breast cancer: Opportunities for pharmacological intervention. Br. J. Pharmacol. 2014, 171, 945–960. [CrossRef] [PubMed]
5. Berridge, M.J.; Bootman, M.D.; Roderick, H.L. Calcium signalling: Dynamics, homeostasis and remodelling. Nat. Rev. Mol. Cell Biol. 2003, 4, 517–529. [CrossRef] [PubMed]
6. Berridge, M.J.; Lipp, P.; Bootman, M.D. The versatility and universality of calcium signalling. Nat. Rev. Mol. Cell Biol. 2000, 1, 11–21. [CrossRef] [PubMed]
7. Berridge, M.J. The AM and FM of calcium signalling. Nature 1997, 386, 759–760. [CrossRef] [PubMed]
8. Bootman, M.D.; Collins, T.J.; Peppiatt, C.M.; Prothero, L.S.; MacKenzie, L.; De Smet, P.; Travers, M.; Tovey, S.C.; Seo, J.T.; Berridge, M.J.; et al. Calcium signalling—An overview. In Seminars in Cell & Developmental Biology; Elsevier: Amsterdam, The Netherlands, 2001.
9. Kadio, B.; Yaya, S.; Basak, A.; Dje, K.; Gomes, J.; Mesenge, C. Calcium role in human carcinogenesis: A comprehensive analysis and critical review of literature. Cancer Metastasis Rev. 2016, 35, 391–411. [CrossRef] [PubMed]
10. Aggarwal, B.B.; Bhardwaj, A.; Aggarwal, R.S.; Seeram, N.P.; Shishodia, S.; Takada, Y. Role of resveratrol in prevention and therapy of cancer: Preclinical and clinical studies. Anticancer Res. 2004, 24, 2783–2840. [PubMed]
11. Renaud, S.D.; de Lorgeril, M. Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet 1992, 339, 1523–1526. [CrossRef]
12. Cottart, C.H.; Nivet-Antoine, V.; Laguillier-Morizot, C.; Beaudeux, J.L. Resveratrol bioavailability and toxicity in humans. Mol. Nutr. Food Res. 2010, 54, 7–16. [CrossRef] [PubMed]
13. Wu, J.M.; Hsieh, T. . Resveratrol: A cardioprotective substance. Ann. N. Y. Acad. Sci. 2011, 1215, 16–21. [CrossRef] [PubMed]
14. Bhatt, J.K.; Thomas, S.; Nanjan, M.J. Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus. Nutr. Res. 2012, 32, 537–541. [CrossRef] [PubMed]
15. Tome-Carneiro, J.; Larrosa, M.; González-Sarrías, A.; Tomás-Barberán, F.A.; García-Conesa, M.T.; Espín, J.C. Resveratrol and clinical trials: The crossroad from in vitro studies to human evidence. Curr. Pharm. Des. 2013, 19, 6064–6093. [CrossRef] [PubMed]
16. McCalley, A.E.; Kaja, S.; Payne, A.J.; Koulen, P. Resveratrol and calcium signaling: Molecular mechanisms and clinical relevance. Molecules 2014, 19, 7327–7340. [CrossRef] [PubMed]
17. Wong, Y.; Osmond, G.; Brewer, K.I.; Tyler, D.S.; Andrus, M.B. Synthesis of 4-ester analogs of resveratrol and their evaluation in malignant melanoma and pancreatic cell lines. Bioorg. Med. Chem. Lett. 2010, 20, 1198–1201. [CrossRef] [PubMed]
18. Acerson, M.J.; Fabick, K.M.; Wong, Y.; Blake, C.; Lephart, E.D.; Andrus, M.B. A new synthesis of 4-resveratrol esters and evaluation of the potential for anti-depressant activity. Bioorg. Med. Chem. Lett. 2013, 23, 2941–2944. [CrossRef] [PubMed]
19. Gwak, H.; Kim, S.; Dhanasekaran, D.N.; Song, Y.S. Resveratrol triggers ER stress-mediated apoptosis by disrupting N-linked glycosylation of proteins in ovarian cancer cells. Cancer Lett. 2016, 371, 347–353. [CrossRef] [PubMed]
20. Li, P.; Yang, S.; Dou, M.; Chen, Y.; Zhang, J.; Zhao, X. Synergic effects of artemisinin and resveratrol in cancer cells. J. Cancer Res. Clin. Oncol. 2014, 140, 2065–2075. [CrossRef] [PubMed]
21. 2+ and mCICR-mediated MPT activation in HepG2 cells. Mol. Cell. Biochem. 2007, 302, 99–109. [CrossRef] [PubMed]
22. Sareen, D.; Darjatmoko, S.R.; Albert, D.M.; Polans, A.S. Mitochondria, calcium, and calpain are key mediators of resveratrol-induced apoptosis in breast cancer. Mol. Pharmacol. 2007, 72, 1466–1475. [CrossRef] [PubMed]
23. 2+-ATPase inducing an increase in cytoplasmic calcium. Biochem. Biophys. Rep. 2016, 7, 253–258. [PubMed]
24. Van Ginkel, P.R.; Yan, M.B.; Bhattacharya, S.; Polans, A.S.; Kenealey, J.D. Natural products induce a G protein-mediated calcium pathway activating p53 in cancer cells. Toxicol. Appl. Pharmacol. 2015, 288, 453–462. [CrossRef] [PubMed]
25. Samad, A.; James, A.; Wong, J.; Mankad, P.; Whitehouse, J.; Patel, W.; Alves-Simoes, M.; Siriwardena, A.K.; Bruce, J.I. Insulin protects pancreatic acinar cells from palmitoleic acid-induced cellular injury. J. Biol. Chem. 2014, 289, 23582–23595. [CrossRef] [PubMed]
26. 2+ release channels. Physiol. Rev. 2007, 87, 593–658. [CrossRef] [PubMed]
27. Genka, S.; Deutsch, J.; Shetty, U.H.; Stahle, P.L.; John, V.; Lieberburg, I.M.; Ali-Osman, F.; Rapoport, S.I.; Greig, N.H. Development of lipophilic anticancer agents for the treatment of brain tumors by the esterification of water-soluble chlorambucil. Clin. Exp. Metastasis 1993, 11, 131–140. [CrossRef] [PubMed]
28. 2+-ATPase 2 (PMCA2) regulates breast cancer cell proliferation and sensitivity to doxorubicin. Sci. Rep. 2016, 6. [CrossRef] [PubMed]
29. Dent, R.; Hanna, W.M.; Trudeau, M.; Rawlinson, E.; Sun, P.; Narod, S.A. Pattern of metastatic spread in triple-negative breast cancer. Breast Cancer Res. Treat. 2009, 115, 423–428. [CrossRef] [PubMed]
30. 2+ indicators with greatly improved fluorescence properties. J. Biol. Chem. 1985, 260, 3440–3450. [PubMed]
31. Curry, M.C.; Luk, N.A.; Kenny, P.A.; Roberts-Thomson, S.J.; Monteith, G.R. Distinct regulation of cytoplasmic calcium signals and cell death pathways by different plasma membrane calcium ATPase isoforms in MDA-MB-231 breast cancer cells. J. Biol. Chem. 2012, 287, 28598–28608. [CrossRef] [PubMed]